Ratings Masimo Corporation

Equities

MASI

US5747951003

Real-time Estimate Cboe BZX Other stock markets 12:06:11 2024-04-19 pm EDT			5-day change	1st Jan Change
135.7 ^USD	-0.17%		-1.82%	+15.53%

Apr. 15	Stifel Upgrades Masimo to Buy From Hold, Raises Price Target to $170 From $148	MT
Apr. 08	Apple to Allow Other Payment Options for Music Apps in Europe; Appeals to Overturn Apple Watch Import Ban	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Over the past four months, analysts' average price target has been revised upwards significantly.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.11 times its estimated earnings per share for the ongoing year.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MASIMO CORPORATION	+15.53%	7.19B		C-
SHOCKWAVE MEDICAL, INC.	+71.88%	12.28B		B-
PENUMBRA, INC.	-19.34%	7.81B		C+
GETINGE AB	-5.13%	5.23B		B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+4.54%	4.94B		D+
APT MEDICAL INC.	+17.02%	4.24B		-
ASAHI INTECC CO., LTD.	-25.36%	3.97B		B-
INARI MEDICAL, INC.	-40.12%	2.24B		C
SKAN GROUP AG	-3.47%	1.92B		-
SHENZHEN YHLO BIOTECH CO., LTD.	-8.13%	1.71B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes